Historical Milestones of the Opioid Epidemic
- Pre-1800s & early use
- Before 1800, pain was often viewed philosophically or existentially; clinicians did not emphasize pharmacologic control of pain.
- Early on, opioids and cocaine were used liberally for various ailments (toothache, diarrhea) with little regulation.
- Early 20th century regulation & opiophobia
- The Harrison Narcotic Control Act (1914) was passed in response to rising heroin abuse and iatrogenic morphine dependency, which began to restrict opioid prescribing.
- Throughout the early to mid-1900s, many pain complaints, especially non-cancer pain, were met with skepticism, and clinicians often withheld opioids due to fear of addiction. This led to “opiophobia,” an underuse of opioid analgesics even when clinically indicated.
- Rise of pain advocacy and “pain as the fifth vital sign”
- In the 1990s, mounting concern about undertreatment of pain led to advocacy positioning pain control as a fundamental aspect of quality care.
- The American Pain Society, beginning mid-1990s, and other bodies promoted the concept of pain assessment as a vital sign, encouraging more aggressive use of analgesics.
- The Joint Commission, around 2000, introduced hospital standards emphasizing pain assessment and management, which increased institutional pressure to prescribe opioids.
- Explosive growth in opioid prescriptions and misuse (late 1990s–2000s)
- Pharmaceutical companies aggressively marketed extended-release opioid formulations (e.g. OxyContin) with claims of safety and low addiction risk.
- From 1999 to 2008, opioid overdose deaths nearly quadrupled.
- Between 2000 and 2012, total opioid consumption in the U.S. rose dramatically—from roughly 46,946 kg to about 165,525 kg.
- Consequences and backlash
- Increasing instances of opioid overdoses, oversedation, respiratory depression, and mortality.
- Recognition that long-term safety and efficacy of opioids for chronic non-cancer pain lacked Level I evidence.
- Regulatory and legal responses: Purdue Pharma guilty plea in 2007 for misbranding OxyContin; emerging abuse deterrent formulations; stricter prescribing guidelines; and monitoring programs.
(Jones et al., 2018)
How does American compare to global figures on substance use?
Overdose deaths in the United States remain significantly higher than in other developed nations despite harm reduction efforts (Commonwealth Fund, 2025).
(Commonwealth Fund, 2025)
How has the Opioid epidemic impacted families?
There has been a lot of attention paid to the direct effects of opioid addiction on adults, however the consequences for children, ranging from prenatal exposure to the destabilization of family environments, poses a significant and emerging public health concern (Feder et al., 2019).
Consequences of SUD on children include:
- Opioid misuse in pregnancy resulting in inadequate prenatal care, preterm birth, low birth weight and neonatal abstinence syndrome
- Child poisoning due to accidental ingestion
- Impaired child-parent attachment.
- Financial deprivation due to increased financial strain
- Separation from parents due to incarceration, foster care, medical issues or death
Rising rates of parental opioid misuse and overdose deaths have been accompanied by a parallel increase in adverse childhood experiences (Feder et al., 2019). As substance use disorder increases, more children are subjected to environments marked by instability, neglect, and trauma (Feder et al., 2019). Consequently, a significant number of these children are being placed into foster care systems. Experiencing adverse childhood events during formative years is strongly associated with an elevated risk of cardiovascular disease, substance abuse disorders, and suicide later in life (Feder et al., 2019). This correlation underscores the broader social impact of the opioid epidemic, extending beyond individual users to affect family structures and child welfare on a large scale
Stigma Related to Substance Use Disorders
According to the American Addiction Center (2025), research shows that substance use disorder (SUD) is more stigmatized than other health
conditions. In fact, in a study conducted by Johns Hopkins Bloomberg School of Public Health found:
- 90% of participants reported an unwillingness to have a person with SUD marry into their family, compared to 59% for a person with mental illness.
- 62% of participants report they will work with someone who has a mental illness, while only 22% are willing to work with someone who has a SUD.
- 64% of participants feel that employers should be able to deny employment to people with SUD, compared to 25% for people with mental illness.
- 43% of participants are opposed to giving individuals with SUD affordable health insurance benefits to those afforded the public at-large, compared to only 21% opposed to giving the same benefits to people with mental illness.
- 54% believe landlords should be allowed to deny housing to a person with SUD, compared to only 15% for persons with mental illness.
- 3 in 10 participants believe that recovery from drug addiction is impossible.
(American Addiction Centers, 2025)
Consequences of stigmatization include a decreased likelihood for patients to receive treatment and recovery (American Addiction Centers, 2025).
"In 2023, over 48 million Americans were diagnosed with a substance use disorder but only 4.5% of them received any form of treatment at a facility"
(American Addiction Centers, 2025)
Treatment Options
Harm reduction measures remain crucial to reduce the transmission of infectious diseases and decrease the number of fatalities due to drug overdose (Commonwealth Fund, 2025). This approach prioritizes minimizing the negative health, social, and legal impacts associated with drug use rather than solely focusing on eliminating drug consumption (Commonwealth Fund, 2025). Globally, harm reduction strategies have gained significant traction, reflecting a practical shift in public health policies aimed at addressing complex substance use issues (Commonwealth Fund, 2025). By implementing programs such as needle exchange services, supervised consumption sites, and widespread access to naloxone, many countries have successfully lowered overdose deaths and curbed the spread of infections like HIV and hepatitis C among people who use drugs (Commonwealth Fund, 2025).
References
American Addiction Centers. (2025, March 28). The stigma of addiction.
https://americanaddictioncenters.org/harm-reduction/stigma-of-addiction
Commonwealth Fund. (2025). U.S. overdose deaths remain higher than in other countries: Trend tracking and harm reduction.
Feder, K. A., Letourneau, E. J., & Brook, J. (2019). Children in the Opioid Epidemic: Addressing the Next Generation's Public Health Crisis.
Pediatrics, 143(1), e20181656. https://doi.org/10.1542/peds.2018-1656
Jones, M. R., Viswanath, O., Peck, J., Kaye, A., & Simopoulos, T. (2018). A brief history of the opioid epidemic and strategies for pain
medicine. Pain and Therapy, 7(1), 13–21. https://doi.org/10.1007/s40122-018-0097-6
Substance Abuse and Mental Health Services Administration. (2024). Overdose prevention.
https://www.samhsa.gov/substance-use/treatment/overdose-prevention
Comments
Post a Comment